<DOC>
	<DOCNO>NCT02140333</DOCNO>
	<brief_summary>The purpose study determine whether 100mg erlotinib similar effect compare 150mg erlotinib NSCLC patient EGFR mutation China .</brief_summary>
	<brief_title>Erlotinib 100mg 150mg Treating EGFR Mutated NSCLC</brief_title>
	<detailed_description>In China confirm 150mg Erlotinib effective NSCLC patient wtih EGFR mutation , reduce dose occur patient drug relate side-effects . Thus , seek investigate Chinese patient EGFR mutation whether low dose ( 100mg ) Erlotinib similar efficacy low toxcities compare standad dose ( 150mg ) Erlotinib .</detailed_description>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histological diagnosis NSCLC phase IIIB IV disease ; 2 . Sensitive mutation EGFR gene ( 18 , 19 del , 21 L858R gene mutation ) ( mutation detection method : ARMSPCR , sequence method ) 3 . Never receive antitumor therapy advance stage ; 4 . Never use EGFR inhibitor ; 5 . Measurable disease RECIST criterion ; 6 . Male female patient &gt; =18 year age ; 7 . ECOG karnofsky performance 0~3 , life expectancy great 12 week ; 8 . Patients must accessible treatment followup ; 1 . Previously use EGFR inhibitor 2 . Mix ingredient patient squamous cell carcinoma , small cell lung cancer ; 3 . Allergic erlotinib ; 4 . Nonmeasurable lesion 5 . Pregnant lactating woman ; 6 . Patients factor prevent researcher enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>erlotinib</keyword>
	<keyword>EGFR mutation</keyword>
</DOC>